Vyome Holdings, Inc. (HIND) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.00 (+2.04%), Market cap $0.01B, 52-week low–high $1.88 ~ $14.00.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne.
Financial statements, price targets, institutional (13F) holdings and related news for Vyome Holdings, Inc. are updated in real time on BlackAll Trade.
Vyome Holdings, Inc. trades at $2.00 (+2.04%). Real-time quotes and charts are available on BlackAll Trade.
Vyome Holdings, Inc. has a market cap of about $0.01B.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmac